13:20 , May 9, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Two multigene signatures could help predict responses to Erbitux cetuximab or the generic chemotherapy 5-FU in colorectal cancer patients. In tumor samples from 49 patient-derived xenograft (PDX) mouse models of colorectal cancer,...
07:00 , Aug 4, 2016 |  BC Innovations  |  Finance

2Q16 Public-Private Partnership Roundup

A new consortia revival helped boost public-private partnerships (PPPs) in 2Q16 to the highest total in two years. Newly announced preclinically focused deals jumped 30% over the relatively sluggish first quarter, from 56 PPPs to...
07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Analytics for ALL

With the help of Alacris Theranostics GmbH 's analytical platform for predicting treatment responses in cancer, an international research team identified new treatment options for a rare, fatal form of acute lymphoblastic leukemia (ALL). The...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Company News

Alacris Theranostics, GlaxoSmithKline deal

The companies partnered to apply Alacris' ModCell system to early stage cancer drug development. GlaxoSmithKline will provide Alacris preclinical data from a cancer compound. Alacris will then use its ModCell to determine the effect of...
08:00 , Jan 17, 2011 |  BC Week In Review  |  Company News

Alacris Theranostics, Qiagen deal

Qiagen acquired a minority stake in Alacris and gained an exclusive option to access all biomarkers discovered by Alacris, which is using its modeling system to develop individualized cancer treatment strategies based on genomic profiles....
08:00 , Jan 17, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acorda Therapeutics Inc. (NASDAQ:ACOR) gained $3.20 (12%) to $30.87 on Monday after reporting preliminary 4Q10 and 2010 sales figures for Ampyra dalfampridine of $55.7 million and $141.4 million, respectively. Acorda launched the product...
01:58 , Jan 12, 2011 |  BC Extra  |  Company News

Qiagen in deals with Alacris, EyeSense

Qiagen N.V. (Xetra:QIA; NASDAQ:QGEN) announced separate deals on Tuesday with Alacris Theranostics GmbH (Berlin, Germany) and EyeSense AG (Basel, Switzerland). Qiagen acquired a minority stake in Alacris and gained an exclusive option to access all...